Science
Experimental lung disease drug rentosertib tied to signs of reduced biological aging
A small clinical study linked rentosertib to younger biological markers, Fox News reports.
The short version
- A small pilot study found that patients treated with the lung disease drug rentosertib showed blood protein changes estimating they were biologically three to four years younger.[Fox News]
- Researchers emphasized that the results are preliminary and do not confirm the drug can reverse aging or lengthen human lifespan.[Fox News]
- The therapy was evaluated in 42 patients over 12 weeks, with company officials describing observed side effects as manageable.[Fox News]
- A phase 3 clinical trial examining more than 300 patients is currently underway in China.[Fox News]
Key facts
- In a 12-week study of 42 patients, individuals receiving rentosertib showed blood protein markers estimating they were biologically three to four years younger.[Fox News]
- Rentosertib was developed by Insilico Medicine to treat idiopathic pulmonary fibrosis.[Fox News]
- An Insilico Medicine executive stated that the risks and side effects observed with the drug were manageable.[Fox News]
- The experimental treatment has moved into a year-long phase 3 study with over 300 participants in China.[Fox News]
What remains uncertain
- Whether rentosertib truly reverses biological aging or prolongs life remains unproven due to preliminary findings and a small trial size.[Fox News]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.